Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.35 |
| ▸ | RAB9A | P51151 | 5/20 | 0.35 |
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3747084 | 0.84 | NPC1 (0.38) | NPC1RAB9AMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL6178336 | 0.71 | ALDH1A1 (0.39) | NPC1RAB9AMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL7866168 | 0.70 | MCL1 (0.55) | NPC1RAB9AMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL3753518 | 0.70 | RAB9A (0.50) | NPC1RAB9AMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL13662606 | 0.70 | RAB9A (0.50) | NPC1RAB9AMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL13659599 | 0.68 | MAPT (0.48) | NPC1RAB9AMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL13659648 | 0.67 | NPC1 (0.56) | NPC1RAB9AMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL3747514 | 0.67 | BCKDK (0.51) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL3741269 | 0.67 | MAPK1 (0.55) | NPC1RAB9AMAPTSMN1; SMN2NPSR1 | |
| SCHEMBL6178899 | 0.65 | MAOB (0.43) | NPC1RAB9AMAPTSMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834194-B2 | Metabolic disorders; antidiabetic agents; hypoglycemic agents; obesity; hypotensive agents | ELI LILLY AND COMPANY (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834194-B2 | Metabolic disorders; antidiabetic agents; hypoglycemic agents; obesity; hypotensive agents | ELI LILLY AND COMPANY (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834194-B2 | Metabolic disorders; antidiabetic agents; hypoglycemic agents; obesity; hypotensive agents | ELI LILLY AND COMPANY (US) | 2010-11-16 | — | — | US | disclosed |
| US-20080207691-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| US-20080207691-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| US-20080207691-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| EP-1830840-B1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1830840-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006068991-A1 | CYCLOALKYL LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207691-A1 | Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1 | HSD11B1, HSD17B1, HSD17B10 | NPC1 343/4885RAB9A 2695/4885MAPT 4362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.